Chrysalis Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Chrysalis Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Chrysalis Study Today - Breaking & Trending Today

COMING SOON: Amivantamab + Lazertinib Versus Osimertinib as 1L Treatment in EGFR-Mutated Advanced NSCLC: Primary Results From MARIPOSA

Published: October 30, 2023

Expert oncologist Alex Spira, MD, PhD, FACP, shares his excitement for an upcoming program centered on the MARIPOSA study in advanced NSCLC following the ESMO 2023 annual meeting.

Source: onclive.com

Related Topics:

Lazertinib Versus OsimertinibMutated AdvancedPrimary Results FromNon Small Cell Lung CancerAdvanced NsclcMetastatic NsclcMariposa TrialMariposa StudyEgfr MutatedEgfr MutantCombination TherapyNovel TherapyEgfr TkiTyrosine Kinase InhibitorsMet InhibitorChrysalis StudyChrysalis TrialExon 20Egfr L858rEfficacy DataOverall SurvivalProgression Free SurvivalPfs DataCns DiseaseBrain Metastases